Key result
This review examines the evidence surrounding the risk stratification and treatment of asymptomatic patients with Wolff-Parkinson-White syndrome.
Why the study?
How should asymptomatic patients with Wolff-Parkinson-White syndrome be risk-stratified and treated to prevent sudden cardiac death?
How should asymptomatic patients with Wolff-Parkinson-White syndrome be risk-stratified and treated to prevent sudden cardiac death?
This review discusses the evidence for risk stratification and treatment of asymptomatic patients with Wolff-Parkinson-White syndrome to mitigate the risk of sudden cardiac death.
Evidence synthesis on asymptomatic WPW risk stratification remains limited; leaves open optimal management to prevent sudden death pending prospective trials.
Wolf-Parkinson-White is a condition which is associated with the presence of accessory pathways in the heart’s conduction system. The treatment of patients with Wolff-Parkinson-White syndrome tends to focus on those who have already suffered an arrhythmia because of the accessory pathway whereby the heart’s electrical conduction pathway bypasses the atrioventricular node. The risk of sudden cardiac death is recognized to be less in those without symptomatic arrhythmias. However, the risk of sudden cardiac death still exists. This paper will look at the evidence surrounding the risk stratifi cation and treatment of these asymptomatic patients.
No takes yet. Share an insight, caveat, or question.
Kelly Anne Mash (2007) conducted a review in Wolff-Parkinson-White syndrome. Risk stratification and treatment was evaluated. This review examines the evidence surrounding the risk stratification and treatment of asymptomatic patients with Wolff-Parkinson-White syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: